Home › NDC Lookup › RxCUI directory › RxCUI 251322

Ethosuximide 50 MG/ML Oral Solution — RxCUI 251322

RxNorm drug concept · Semantic clinical drug
RxCUI 251322 Semantic clinical drug · SCD ● Current RxNorm concept 5 FDA products 6 package NDCs Snapshot Jul 14, 2026

This page is curated, coded, and maintained by

Compiled from public NLM RxNorm and FDA (openFDA NDC directory) data sources. Editorial policy

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI251322
Official nameEthosuximide 50 MG/ML Oral Solution
Concept typeSemantic clinical drug (SCD)
RxNorm statusCurrent RxNorm concept
Also known asethosuximide 250 MG per 5 ML Oral Solution; ethosuximide 250 MG in 5 mL Oral Solution
FDA products mapped5
Package NDCs mapped6
Reported Medicaid activity (SDUD)36,880 prescriptions · 52 state & territory Medicaid programs · latest period Q4 2025
RxNorm release07/06/2026
Snapshot dataJul 14, 2026

📖 Skip the Codes — Read It in Plain English.

Our pharmacist-built guide to Ethosuximide: what it is, how it’s used, side effects, and interactions.

📗 Our plain-language guide HelloPharmacist
  • An absence seizure is a brief episode — usually just a few seconds — where you or your child suddenly stares blankly and loses awareness, then snaps back as if nothing happened. Th...
  • What exactly is an absence seizure, and will ethosuximide stop them?
  • Ethosuximide comes as a capsule or a liquid solution, and you take it by mouth. Your doctor will start you on a lower dose and gradually increase it until your seizures are well co...
  • How do I take it, and does it matter if I take it with food?
📖 Read our full Ethosuximide guide →

🕸️ Concept Web — How Ethosuximide 50 MG/ML Oral Solution Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept Ethosuximide 50 MG/ML Oral Solution RxCUI 251322

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

  1. Ingredients 1

    The active substance itself — no strength, form, or brand attached yet.

    • Ethosuximide 4135
  2. Brand names 1

    The same medicine's trade names. A brand name alone says nothing about strength or form.

    • Zarontin 202981
  3. Dose forms 9

    The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.

    • Ethosuximide Oral Solution 372109
    • Ethosuximide Oral Liquid Product 1157373
    • Ethosuximide Oral Product 1157374
    • Ethosuximide Oral Solution [Zarontin] 756862
    • Zarontin Oral Liquid Product 1187042
    • Zarontin Oral Product 1187043
    • Oral Solution 316968
    • Oral Liquid Product 1151137
    • +1 more in this family
  4. Clinical & branded drugs 3

    Ingredient + strength + dose form. These are the concepts real FDA products actually carry.

Showing up to 8 concepts per family — 13 of 14 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

  • Ethosuximide 50 MG/ML SCDC · 315901
  • Ethosuximide Oral Solution SCDF · 372109
  • Ethosuximide Oral Liquid Product SCDG · 1157373
  • Ethosuximide Oral Product SCDG · 1157374

Brand-Name Concepts

  • Ethosuximide 50 MG/ML Oral Solution [Zarontin] SBD · 755357
  • Ethosuximide 50 MG/ML [Zarontin] SBDC · 565633
  • Ethosuximide Oral Solution [Zarontin] SBDF · 756862
  • Zarontin Oral Liquid Product SBDG · 1187042
  • Zarontin Oral Product SBDG · 1187043
  • Zarontin BN · 202981

📦 FDA Products & Package NDCs

5 products · 6 package NDCs
6 package NDCs map to RxCUI 251322 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
Package NDC Package Brand / generic name Labeler Marketing start
00071-2418-19 1 BOTTLE, PLASTIC in 1 CARTON (0071-2418-19) / 474 mL in 1... Zarontin Parke-Davis Div of Pfizer Inc 2022-06-01
00121-0670-16 473 mL in 1 BOTTLE (0121-0670-16) ETHOSUXIMIDE PAI Holdings, LLC dba PAI Pharma 2000-11-22
59762-2350-06 1 BOTTLE, PLASTIC in 1 CARTON (59762-2350-6) / 474 mL in 1... Ethosuximide Mylan Pharmaceuticals Inc. 2020-02-21
59762-2350-07 1 BOTTLE, PLASTIC in 1 CARTON (59762-2350-7) / 474 mL in 1... Ethosuximide Mylan Pharmaceuticals Inc. 2022-07-01
62135-0064-47 473 mL in 1 BOTTLE (62135-064-47) Ethosuximide Chartwell RX, LLC 2026-05-20
68999-0064-24 2 TRAY in 1 BOX (68999-064-24) / 10 CUP in 1 TRAY / 5 mL in... Ethosuximide Chartwell Governmental & Specialty RX, LLC. 2026-06-09
Observed labelers: Mylan Pharmaceuticals Inc. (2) · Chartwell Governmental & Specialty RX, LLC. (1) · Chartwell RX, LLC (1) · PAI Holdings, LLC dba PAI Pharma (1) · Parke-Davis Div of Pfizer Inc (1) — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

💲 Pricing (NADAC)

NADAC is CMS's National Average Drug Acquisition Cost — roughly what pharmacies pay to buy the drug. It is an acquisition benchmark, not your copay.
Per ml · median
$0.0893
Range $0.0893–$0.0893 · middle 50% $0.0893–$0.0893 · 2 NDCs
Latest compatible distributions from the CMS NADAC file · dataset watermark 2026-07-10. Prices vary by package and pharmacy; a distribution is shown instead of one misleading number. Rows the dataset is silent on carry no price. No zero-cost conclusion should be drawn.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
  • A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
  • Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
  • Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
  • Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.